Glycotargeting therapeutics

Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.


Year:
2017
Other identifiers:
EPO Family ID: 57730362
EPO Family ID: 56692928
EPO Family ID: 53762221
EPO Family ID: 57121450
TTO: 6.1372
Laboratories:




 Record created 2017-05-02, last modified 2018-03-18


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)